The AMBAR study

 

The AMBAR study

AMBAR is an international and multicenter clinical trial designed by Grifols in collaboration with Fundació ACE in Barcelona, Spain; and the Alzheimer Disease Research Center in Pittsburgh, PA, U.S. Following a successful pilot, phase I and phase II, phase IIb/III of the trial aimed to evaluate the efficacy of plasma exchange to slow the progression of Alzheimer's.

Phase IIb/III of the trial has been carried out in 41 hospitals across the U.S. and Spain, with 496 patients with mild and moderate Alzheimer's taking part. The study was double-blind –neither patients nor evaluators knew who was receiving which treatment– and placebo-controlled.

AMBAR was designed to evaluate the efficacy of plasma exchange using different replacement volumes and concentrations of albumin.

The treatment lasted 14 months and was split into two phases: an initial phase common to all patients, followed by a second phase in which different volumes and concentrations of albumin were administered to different groups. In some cases, the albumin was alternated with intravenous immunoglobulin to correct a possible endogenous immunoglobulin decrease. The plasma exchange in placebo-controlled group was simulated in both phases.

The primary objectives were to evaluate the efficacy of the treatment by measuring variations in the patients' cognitive function and ability to carry out daily activities.

496
patients with Alzheimer

mild to moderate stage

41
hospitals

22 in the US & 19 in Spain

14
months

of treatment

496
patients with Alzheimer

mild to moderate stage

41
hospitals

22 in the US & 19 in Spain

14
months

of treatment

"Grifols will continue to explore the potential of plasma proteins and plasma exchange in further studies."

Víctor Grífols, Grifols Chairman

"The results are positive and highly relevant in a cohort of patients suffering from moderate Alzheimer disease."

Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program

"This is the most significant development in the treatment of patients with moderate Alzheimer's disease I've seen in over 15 years."

Mercè Boada, M.D., Ph.D., Director of Fundació ACE.

"Grifols will continue to explore the potential of plasma proteins and plasma exchange in further studies."

Víctor Grífols, Grifols Chairman

"The results are positive and highly relevant in a cohort of patients suffering from moderate Alzheimer disease."

Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program

"This is the most significant development in the treatment of patients with moderate Alzheimer's disease I've seen in over 15 years."

Mercè Boada, M.D., Ph.D., Director of Fundació ACE.

Long-term, sustainable vision

As our business continues to grow, we remain committed to a long-term, sustainable and responsible vision.

We strive to be a global leader in our markets and a constant industry reference for innovation, quality and safety.

Quality and safety

Our products help ensure the health and quality of life of patients. For this reason, safety is more than just a regulatory requirement at Grifols. Safety is a philosophy that goes hand in hand with our commitment to integrity in everything we do.

The quality and safety of our products and of our internal processes are of pivotal importance to our organization.

Clinical Study Design

The video explains the characteristics of the study and how the clinical trial has been carried out.

Alzheimer's disease infographic Alzheimer's disease infographic